Published in Antimicrob Agents Chemother on May 01, 1988
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Chemother (1989) 2.63
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother (1990) 1.98
WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob Agents Chemother (1990) 1.23
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob Agents Chemother (1991) 1.04
In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1993) 1.00
Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1990) 0.96
Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones. Antimicrob Agents Chemother (1996) 0.90
Discovery and development of new antimicrobial agents. Clin Microbiol Rev (1990) 0.87
E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. Antimicrob Agents Chemother (1995) 0.82
In vitro activities of irloxacin and E-3846, two new quinolones. Antimicrob Agents Chemother (1990) 0.75
In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother (1980) 26.28
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol (1983) 8.38
In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother (1983) 6.29
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1983) 5.21
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother (1984) 4.13
In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother (1983) 3.80
In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother (1984) 3.62
[A new synthetic antibacterial : 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.)]. C R Seances Acad Sci III (1981) 3.04
The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol (1984) 2.22
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 2.02
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice. Antimicrob Agents Chemother (1983) 1.90
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing. Diagn Microbiol Infect Dis (1983) 1.83
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 1.81
In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin. Antimicrob Agents Chemother (1984) 1.39
Antimicrobial spectrum of Win 49375. Antimicrob Agents Chemother (1984) 1.31
In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates. Drugs Exp Clin Res (1987) 1.17
Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance. J Antimicrob Chemother (1984) 1.16
In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin). Antimicrob Agents Chemother (1985) 1.07
An experimental model for ascending acute pyelonephritis caused by Escherichia coli or proteus in rats. J Clin Pathol (1980) 1.05
Bioassay procedures for norfloxacin. Eur J Clin Microbiol (1983) 0.97
In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates. Drugs Exp Clin Res (1987) 0.97
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther (2011) 3.16
Heatstroke: its clinical picture and mechanism in 36 cases. Q J Med (1967) 3.08
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut (2010) 2.98
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect (2014) 2.47
Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up. Am J Gastroenterol (2000) 2.32
Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol (1999) 2.32
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 2.22
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect (2014) 1.70
Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology (1990) 1.59
[Impact of control measures on the course of an outbreak of methicillin-resistant Staphylococcus aureus]. Med Clin (Barc) (1997) 1.46
Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea. Aliment Pharmacol Ther (2015) 1.41
[The evidence of human immunodeficiency virus infection in the seronegative subjects of high-risk groups]. Med Clin (Barc) (1991) 1.40
[Study of 164 episodes of infectious endocarditis in drug addicts: comparison of HIV positive and negative patients]. Rev Clin Esp (1994) 1.38
Study of the interference of haemolysis in the determination of creatinine in the Technicon DAX-72 (Bayer) Eur J Clin Chem Clin Biochem (1997) 1.38
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect (2014) 1.36
Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol (1989) 1.27
In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates. Drugs Exp Clin Res (1987) 1.17
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother (2004) 1.16
Retracted Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol (2010) 1.16
Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.15
Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol (2005) 1.11
Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Gut (1996) 1.08
Cardiac involvement in psittacosis. Br Med J (1967) 1.08
Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut (1993) 1.06
In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother (2009) 1.05
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob Agents Chemother (1991) 1.04
Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig Dis Sci (2001) 1.01
In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1993) 1.00
[Secretion of amino acids by the Citrobacter intermedium strain]. Microbiol Esp (1969) 0.99
Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis (2008) 0.98
The prevalence of coeliac disease is significantly higher in children compared with adults. Aliment Pharmacol Ther (2010) 0.98
Glucose-6-phosphate dehydrogenase alloenzymes and their relationship to pigmentation in Serratia marcescens. Appl Environ Microbiol (1987) 0.98
Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect (2010) 0.97
In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates. Drugs Exp Clin Res (1987) 0.97
Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1990) 0.96
Diagnostic value of duodenal antitissue transglutaminase antibodies in gluten-sensitive enteropathy. Aliment Pharmacol Ther (2008) 0.95
Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol (2002) 0.95
[Colony analysis of the production of glutamic acid by Citrobacter intermedium C3]. Microbiol Esp (1971) 0.94
Endoscopic treatment with self-expanding metal stents for Crohn’s disease strictures. Aliment Pharmacol Ther (2012) 0.94
Effect of oral oleoyl-estrone on adipose tissue composition in male rats. Int J Obes Relat Metab Disord (2002) 0.93
Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol (1993) 0.93
Pseudoalteromonas antarctica sp. nov., isolated from an Antarctic coastal environment. Int J Syst Bacteriol (1997) 0.93
Brown pigmentation in Serratia marcescens cultures associated with tyrosine metabolism. Can J Microbiol (1989) 0.91
Antibacterial activity and pharmacokinetics of four new 7-azetidinyl fluoroquinolones. Antimicrob Agents Chemother (1996) 0.90
Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. Am J Gastroenterol (2002) 0.90
Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther (2013) 0.89
Granulomatous interstitial nephritis secondary to allopurinol treatment. Clin Nephrol (1995) 0.89
Combined effects of oral oleoyl-estrone and limited food intake on body composition of young overweight male rats. Int J Obes (Lond) (2006) 0.88
Quality of life in severe chronic obstructive pulmonary disease: correlation with lung and muscle function. Respir Med (1998) 0.88
Daily oral oleoyl-estrone gavage induces a dose-dependent loss of fat in Wistar rats. Obes Res (2001) 0.88
Factors related to the plasma fatty acid profile in healthy subjects, with special reference to antioxidant micronutrient status: a multivariate analysis. Am J Clin Nutr (1992) 0.87
Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis. Gut (2000) 0.87
Plasma amino acids of lean and obese Zucker rats subjected to a cafeteria diet after weaning. Biochem Int (1991) 0.86
[Bilateral tension pneumothorax after retrieval of transtracheal jet ventilation catheter]. Ann Fr Anesth Reanim (2006) 0.86
A new episomic element controlling fermentative metabolism and excretion of amino acids by Citrobacter intermedium C3. J Bacteriol (1974) 0.86
Hypercalcemic crisis in gallbladder cancer. Acta Gastroenterol Belg (1987) 0.85
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin Transl Oncol (2013) 0.85
Whole-rat protein content estimation: applicability of the N x 6.25 factor. Br J Nutr (1994) 0.85
Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. Hepatology (1991) 0.85
Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infections. Int J Nanomedicine (2012) 0.84
Serum zinc, copper, and selenium levels in inflammatory bowel disease: effect of total enteral nutrition on trace element status. Am J Gastroenterol (1990) 0.84
Burns in the elderly. Burns (1989) 0.84
Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. Clin Infect Dis (2012) 0.83
Production and Rheological Properties of the Extracellular Polysaccharide Synthesized by Pseudomonas sp. Strain EPS-5028. Appl Environ Microbiol (1986) 0.83
Antimicrobial activity of E-4441, a representative azetidine quinolone. Drugs Exp Clin Res (1990) 0.83
Functionalized Fe₃O₄@Au superparamagnetic nanoparticles: in vitro bioactivity. Nanotechnology (2012) 0.83
Rat insulin turnover in vivo. Endocrinology (1995) 0.83
Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. Am J Gastroenterol (1998) 0.83
[Production of alanine by fermentation with Citrobacter intermedium C3]. Rev Esp Fisiol (1969) 0.82
Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Med Mycol (2008) 0.82
Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis. Gut (1996) 0.82
E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. Antimicrob Agents Chemother (1995) 0.82
Short-term oral oleoyl-estrone treatment increases plasma cholesterol turnover in the rat. Int J Obes (Lond) (2005) 0.81
The effect of total enteral tube feeding on the vitamin status of malnourished patients with inflammatory bowel disease. Int J Vitam Nutr Res (1988) 0.81
Polyphasic taxonomy of a novel yeast isolated from antarctic environment; description of Cryptococcus victoriae sp. nov. Syst Appl Microbiol (1999) 0.81
Sequential esophageal motility studies after endoscopic injection sclerotherapy: a prospective investigation. Am J Gastroenterol (1991) 0.81
Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis (2011) 0.81